| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | -100.0% | — |
| R&D Expense | $68.3M | +6.8% | -10.9% |
| SG&A Expense | $12.1M | -11.0% | -38.6% |
| Operating Income | -$80.4M | -4.6% | +16.6% |
| Net Income | -$74.1M | -5.4% | +15.8% |
| EPS (Basic) | -$0.43 | -4.9% | +31.7% |
| EPS (Diluted) | -$0.43 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $91.6M | -19.6% | -39.9% |
| Current Assets | $624.0M | -8.3% | -27.9% |
| Total Assets | $670.0M | -8.1% | -28.0% |
| Current Liabilities | $32.6M | +0.2% | -30.6% |
| Total Liabilities | $62.3M | -1.4% | -31.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$190.6M | — | — |
| Capital Expenditures | $409K | — | — |
| Investing Cash Flow | $157.3M | — | — |
| Financing Cash Flow | $670K | — | — |
| Free Cash Flow | -$191.0M | — | — |
| +31.7% |
| $607.7M |
| -8.7% |
| -27.6% |